Encompass Health (EHC) Q2 Revenue Up 12%

Encompass Health (EHC) reported robust Q2 2025 results, with GAAP revenue of $1.46 billion, up 12.0% year-over-year and exceeding consensus, alongside non-GAAP EPS of $1.40, a 26.1% increase year-over-year that topped estimates. This strong performance was driven by a 7.2% rise in patient discharges, a favorable shift in payer mix towards higher-reimbursement government programs, and enhanced operational efficiency. In response, management raised its full-year 2025 guidance for revenue, adjusted EBITDA, and non-GAAP EPS, signaling confidence in sustained demand and ongoing strategic expansion initiatives.

Analysis

Encompass Health (EHC) delivered a robust second quarter for 2025, significantly outperforming consensus estimates and demonstrating strong fundamental momentum. Revenue grew 12.0% year-over-year to $1.46 billion, driven by a 7.2% increase in patient discharges and a 4.2% rise in revenue per discharge. This top-line strength was amplified by favorable operational leverage, including record efficiency in labor utilization and a favorable payer mix shift toward higher-reimbursement Medicare programs, which grew by 1.5 percentage points as a share of the mix. Consequently, non-GAAP EPS surged 26.1% to $1.40, and Adjusted EBITDA increased 17.2%. Management's confidence is underscored by a material increase in full-year 2025 guidance for revenue, adjusted EBITDA, and non-GAAP EPS. The company's financial health appears solid, with adjusted free cash flow growing 30.5% and net leverage declining to 2.1x, providing ample capacity to internally fund its strategic expansion of 6-10 new hospitals per year.

Key Decisions for Investors

• The comprehensive beat on revenue and EPS, coupled with a significant raise in full-year guidance, reinforces the positive investment thesis based on strong operational execution and market demand.
• Investors should monitor labor cost trends and the sustainability of record operational efficiencies, as well as the finalization of the proposed 2.6% Medicare rate update for FY2026, which represents a key potential catalyst for future revenue.
• The company's ability to fund its expansion pipeline with internal cash flow while simultaneously reducing net leverage suggests a self-sustaining growth model that warrants attention for long-term oriented investors.